Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Weight Loss Plateaus Are Normal and Seen in Every Major GLP-1/GIP Study The Standard Weight-Loss Curve Clinical trials consistently show that weight loss with GLP-1 and GLP-1/GIP medications follows a predictable pattern: Rapid weight loss early Gradual slowing over time A plateau phase where weight stabilizes This pattern has been observed across: Semaglutide trials ( STEP program ) Tirzepatide trials ( SURMOUNT-1 , SURMOUNT-4 ) Long-term cardiovascular outcomes studies ( SELECT ) In these studies, most participants lost weight more rapidly during the first several months, then experienced a gradual slowing and reached their average maximum weight loss around 918 months , after which weight tended to stabilize rather than continue to drop indefinitely
A recent clinical study found that people who exercised while taking medications like Ozempic were more likely to keep weight off and regained less weight if they eventually stopped the medication, compared to those who didnt exercise
Get your gut moving so you can keep moving toward your goals
As evidence accruesfrom real-world adverse event reports to new peer-reviewed researchattorneys anticipate a substantial increase in claims involving Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 medications in the months ahead
The generic name for Ozempic is semaglutide, and when patients take it for weight loss, its called Wegovy
